secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2026-08-13T20:11:08+00:00
Accession:  0001193125-26-349193
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd Q2 2026 revenue up 21% to $14.3M; net loss widens to $44.4M; PEMGARDA EUA termination notice
--------------------------------------------------------------------------------

- Q2 2026 PEMGARDA net product revenue $14.3M, up 21% YoY from $11.8M.
- Net loss $44.4M vs $14.7M; EPS -$0.14 vs -$0.12; R&D spend $29.4M vs $9.6M.
- Cash $160.1M; runway through DECLARATION data readout and potential VYD2311 launch.
- Received 12-month notice of PEMGARDA EUA termination in July 2026; in dialogue with FDA.
- DECLARATION enrollment complete, top-line data later Q3 2026; LIBERTY fully dosed, top-line late Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/0001193125-26-349193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer